Global Next Generation Antibody Therapeutics Market Report 2024, Forecast To 2033
8 Mar, 2024
The next-generation antibody therapeutics market grew from $6.14 billion in 2023 to $6.9 billion in 2024, with a CAGR of 12.4%. Anticipated to reach $10.41 billion in 2028, propelled by biosimilar development and nanobody adoption.
Global Next Generation Antibody Therapeutics Market Key Driver
The next-generation antibody therapeutics market is poised for growth due to the increasing prevalence of chronic diseases. By 2050, the number of individuals aged 50 and older with chronic illnesses is projected to surge by 99.5%. This rise in chronic conditions fuels the demand for advanced antibody therapeutics, providing targeted care. Thus, the market for next-generation antibody therapeutics grows in response to chronic disease prevalence.
Get A Free Sample Of The Global Next Generation Antibody Therapeutics Market ReportGlobal Next Generation Antibody Therapeutics Market Segments
The next-generation antibody therapeutics market covered in this report is segmented –
1) Types Of Antibodies:Monoclonal Antibodies, Polyclonal Antibodies, Biospecific Antibodies, Antibody-Drug Conjugates, Other Types
2) Therapeutic Area:Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas
3) End-User:Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users
By Geography: The countries covered in the next-generation antibody therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the next-generation antibody therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Next Generation Antibody Therapeutics Industry Players
Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Bayer AG; Bristol-Myers Squibb Company; AstraZeneca plc; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Gilead Sciences Inc.; Boehringer Ingelheim International GmbH; Amgen Inc.; Moderna Inc.; BioNTech SE; Regeneron Pharmaceuticals Inc.; Biogen Inc.; Celgene Corporation; Lonza Group AG; Catalent Inc.; Genentech Inc.; Kyowa Hakko Kirin Co. Ltd.; Samsung Biologics; WuXi Biologics; Seagen Inc.; Seattle Genetics Inc.; Xencor Inc.; ImmunoGen Inc.
Get The Full Global Next Generation Antibody Therapeutics Market Report
Next Generation Antibody Therapeutics Market Overview
Next-generation antibody therapeutics are advanced antibody-based drugs in structure, functionality, and therapeutic potential beyond traditional monoclonal antibodies. It treats several severe medical problems, including cancer, infectious infections, and immunological disorders.